Aardvark Therapeutics, Inc. (NASDAQ:AARD – Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 1,038,938 shares, an increase of 87.8% from the October 15th total of 553,262 shares. Based on an average daily volume of 2,760,064 shares, the short-interest ratio is presently 0.4 days. Currently, 5.8% of the company’s shares are short sold.
Insider Transactions at Aardvark Therapeutics
In related news, insider Nelson Sun sold 62,000 shares of the firm’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $5.18, for a total transaction of $321,160.00. Following the completion of the sale, the insider directly owned 35,475 shares in the company, valued at approximately $183,760.50. This trade represents a 63.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 17.80% of the company’s stock.
Institutional Investors Weigh In On Aardvark Therapeutics
A number of institutional investors have recently modified their holdings of AARD. Empowered Funds LLC acquired a new position in Aardvark Therapeutics during the 3rd quarter worth about $124,000. Susquehanna International Group LLP acquired a new position in Aardvark Therapeutics in the 2nd quarter valued at about $138,000. Bank of New York Mellon Corp increased its stake in Aardvark Therapeutics by 30.8% during the first quarter. Bank of New York Mellon Corp now owns 29,320 shares of the company’s stock worth $111,000 after purchasing an additional 6,905 shares during the period. Ieq Capital LLC acquired a new stake in shares of Aardvark Therapeutics during the second quarter worth about $221,000. Finally, J. Goldman & Co LP acquired a new stake in shares of Aardvark Therapeutics during the second quarter worth about $233,000.
Wall Street Analysts Forecast Growth
AARD has been the subject of a number of recent analyst reports. Raymond James Financial restated a “market perform” rating on shares of Aardvark Therapeutics in a report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Tuesday, September 29th. Oppenheimer lowered Aardvark Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, October 26th. UBS Group set a $4.00 price target on Aardvark Therapeutics in a research note on Monday, October 19th. Finally, Wall Street Zen cut Aardvark Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Two research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $11.56.
Check Out Our Latest Stock Analysis on AARD
Aardvark Therapeutics Price Performance
Shares of NASDAQ:AARD traded down $0.19 during mid-day trading on Friday, reaching $1.33. 402,447 shares of the company were exchanged, compared to its average volume of 1,698,199. The firm has a market cap of $29.10 million, a price-to-earnings ratio of -0.41 and a beta of 4.38. The firm’s 50-day simple moving average is $3.76 and its 200 day simple moving average is $5.72. Aardvark Therapeutics has a 1 year low of $0.93 and a 1 year high of $16.60.
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.19). On average, research analysts forecast that Aardvark Therapeutics will post -3.05 earnings per share for the current fiscal year.
About Aardvark Therapeutics
Aardvark Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance. The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity.
Featured Stories
- Five stocks we like better than Aardvark Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
